Clinical, Metabolic and Molecular Physiology Research Group, MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Royal Derby Hospital Centre, University of Nottingham, Derby DE22 6DT, UK.
National Institute for Health Research (NIHR), Nottingham Biomedical Research Centre, Nottingham NG7 2UH, UK.
Nutrients. 2022 Oct 20;14(20):4411. doi: 10.3390/nu14204411.
Introduction: Recent studies have concluded that elevated circulating branched chain amino acids (BCAA) are associated with the pathogenesis of type 2 diabetes mellitus (T2DM) and obesity. However, the development of this association over time and the quantification of the strength of this association for individual BCAAs prior to T2DM diagnosis remains unexplored. Methods: A systematic search was conducted using the Healthcare Databases Advance Search (HDAS) via the National Institute for Health and Care Excellence (NICE) website. The data sources included EMBASE, MEDLINE and PubMed for all papers from inception until November 2021. Nine studies were identified in this systematic review and meta-analysis. Stratification was based on follow-up times (0−6, 6−12 and 12 or more years) and controlling of body mass index (BMI) through the specific assessment of overweight cohorts was also undertaken. Results: The meta-analysis revealed a statistically significant positive association between BCAA concentrations and the development of T2DM, with valine OR = 2.08 (95% CI = 2.04−2.12, p < 0.00001), leucine OR = 2.25 (95% CI = 1.76−2.87, p < 0.00001) and isoleucine OR = 2.12, 95% CI = 2.00−2.25, p < 0.00001. In addition, we demonstrated a positive consistent temporal association between circulating BCAA levels and the risk of developing T2DM with differentials in the respective follow-up times of 0−6 years, 6−12 years and ≥12 years follow-up for valine (OR = 2.08, 1.86 and 2.14, p < 0.05 each), leucine (OR = 2.10, 2.25 and 2.16, p < 0.05 each) and isoleucine (OR = 2.12, 1.90 and 2.16, p < 0.05 each) demonstrated. Conclusion: Plasma BCAA concentrations are associated with T2DM incidence across all temporal subgroups. We suggest the potential utility of BCAAs as an early biomarker for T2DM irrespective of follow-up time.
最近的研究表明,循环支链氨基酸(BCAA)水平升高与 2 型糖尿病(T2DM)和肥胖的发病机制有关。然而,这种关联随时间的发展以及在 T2DM 诊断前对个体 BCAA 关联强度的定量仍未得到探索。
通过国家卫生与保健卓越研究所(NICE)网站使用医疗保健数据库高级搜索(HDAS)进行系统检索。数据来源包括 EMBASE、MEDLINE 和 PubMed,检索时间从建库开始至 2021 年 11 月。本系统评价和荟萃分析共确定了 9 项研究。分层基于随访时间(0−6、6−12 和 12 年或更长时间),并通过对超重队列的具体评估来控制体重指数(BMI)。
荟萃分析显示,BCAA 浓度与 T2DM 的发生之间存在统计学上显著的正相关,缬氨酸 OR = 2.08(95%CI = 2.04−2.12,p < 0.00001),亮氨酸 OR = 2.25(95%CI = 1.76−2.87,p < 0.00001)和异亮氨酸 OR = 2.12,95%CI = 2.00−2.25,p < 0.00001。此外,我们还证明了循环 BCAA 水平与 T2DM 发病风险之间存在一致的正向时间关联,不同随访时间的差异为 0−6 年、6−12 年和≥12 年随访的缬氨酸(OR = 2.08、1.86 和 2.14,p < 0.05 各)、亮氨酸(OR = 2.10、2.25 和 2.16,p < 0.05 各)和异亮氨酸(OR = 2.12、1.90 和 2.16,p < 0.05 各)。
血浆 BCAA 浓度与所有时间亚组的 T2DM 发生率相关。我们建议将 BCAA 作为 T2DM 的早期生物标志物具有潜在的应用价值,而与随访时间无关。